Agios Pharmaceuticals Inc [AGIO] stock is trading at $30.11, down -0.20%. An important factor to consider is whether the stock is rising or falling in short-term value. The AGIO shares have gain 7.42% over the last week, with a monthly amount glided 7.54%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Agios Pharmaceuticals Inc [NASDAQ: AGIO] stock has seen the most recent analyst activity on February 24, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $58. Leerink Partners downgraded its rating to a Market Perform and decreased its price target to $56 on September 27, 2024. Cantor Fitzgerald initiated its recommendation with a Overweight. Piper Sandler started tracking with a Overweight rating for this stock on February 03, 2023, and assigned it a price target of $41. In a note dated November 17, 2022, Goldman upgraded an Neutral rating on this stock and boosted its target price from $17 to $32.
Agios Pharmaceuticals Inc [AGIO] stock has fluctuated between $23.42 and $62.58 over the past year. Currently, Wall Street analysts expect the stock to reach $71 within the next 12 months. Agios Pharmaceuticals Inc [NASDAQ: AGIO] shares were valued at $30.11 at the most recent close of the market. An investor can expect a potential return of 135.8% based on the average AGIO price forecast.
Analyzing the AGIO fundamentals
Agios Pharmaceuticals Inc [NASDAQ:AGIO] reported sales of 37.03M for the trailing twelve months, which represents a growth of 6.56%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -11.89%, Pretax Profit Margin comes in at 19.18%, and Net Profit Margin reading is 17.98%. To continue investigating profitability, this company’s Return on Assets is posted at 0.43, Equity is 0.5 and Total Capital is -0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Agios Pharmaceuticals Inc’s Current Ratio is 18.50. On the other hand, the Quick Ratio is 17.93, and the Cash Ratio is 1.51. Considering the valuation of this stock, the price to sales ratio is 47.09, the price to book ratio is 1.19 and price to earnings (TTM) ratio is 2.67.
Transactions by insiders
Recent insider trading involved FOUSE JACQUALYN A, Director, that happened on Apr 10 ’25 when 7497.0 shares were sold. Director, FOUSE JACQUALYN A completed a deal on Apr 08 ’25 to buy 7497.0 shares. Meanwhile, Chief Legal Officer Burns James William sold 4005.0 shares on Mar 03 ’25.
